Aiqin Gu

机构：Shanghai Chest Hospital

发表论文 6 篇 · 总被引 27 次 · h-index 3

代表论文

• Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer (2025 · Signal Transduction and Targeted Therapy · 被引 12)
• Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study (2024 · BMC Cancer · 被引 8)
• Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN). (2022 · Journal of Clinical Oncology · 被引 5)
• Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma (2024 · Cancer Nanotechnology · 被引 1)
• Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial (2026 · Frontiers in Pharmacology)
• MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy. (2024 · Journal of Clinical Oncology)